At the core of this advance lies the meticulous exploration of OppA’s binding pocket, revealed by high-resolution crystallographic data showing a spacious cavity capable of accommodating peptide substrates extending from the serine side chain to the N-terminal glycine residue. This insight sparked a hypothesis that the transporter’s substrate flexibility could extend to non-canonical side chains beyond the natural amino acid repertoire, thus enabling the shuttling of diverse synthetic peptides conjugated with ncAAs into the bacterial cytosol.

To test this concept, the researchers designed and synthesized a panel of 14 tripeptides with a generic scaffold designated Z-AisoK, wherein Z represents varied amino acid residues, including both canonical and non-canonical entities. These Z residues were strategically positioned at the N-terminus to probe the structural tolerance of OppA for bulkier or chemically distinct side chains. Importantly, the incorporation of these Z-AisoK tripeptides into cells led to the intracellular generation of both the liberated Z residue and the bio-orthogonal amino acid AisoK.

Functional validation was carried out by measuring the amber suppression efficiency using a reporter system involving sfGFP (superfolder green fluorescent protein) harboring an amber stop codon at position 150. Successful suppression, indicative of ncAA incorporation, was observed for over half of the synthesized tripeptides in wild-type E. coli K12, demonstrating the viability of this transport-mediated delivery route. Supplementary liquid chromatography-mass spectrometry (LC-MS) confirmed the presence of AisoK within expressed proteins, ensuring that surface-level fluorescence data were consistent with bona fide incorporation.

However, the strategy faced challenges with tripeptides containing bulkier or negatively charged Z residues, which exhibited poor or negligible uptake and cleavage, as evidenced by dramatically reduced amber suppression efficiency. This limitation led the team to engineer the OppA transporter itself through directed evolution techniques, targeting four amino acid residues surrounding the glycine moiety in the G-SisoK substrate to expand binding pocket dimensions and enhance accommodation of larger or charged side chains.

This rational mutagenesis, combined with three rounds of fluorescence-activated cell sorting (FACS) enrichment, yielded two evolved transporter variants, coined OppA-Z1 and OppA-Z2, each tailored to different subsets of challenging substrates. Both variants featured reduced side chain bulkiness at critical positions, enlarging the pocket, while OppA-Z2 uniquely harbored a spontaneous R439H mutation that likely contributed to improved affinity for isopeptide-linked substrates. The engineered E. coli strains expressing these variants demonstrated marked improvements in the uptake and subsequent incorporation of previously impermeable ncAA-bearing peptides.

The most significant breakthrough was observed with OppA-Z2-expressing cells, which efficiently internalized all tested Z-AisoK tripeptides, including those with negatively charged residues such as succinyl-lysine and glutamyl-lysine analogs. This finding underscores the broad substrate scope achievable through transporter engineering, significantly widening the chemical diversity accessible for genetic code expansion in living bacterial systems. The ability to utilize charged and bulky ncAAs intracellularly opens exciting avenues for the creation of proteins with complex, post-translationally modified-like features that were previously inaccessible.

Comparative analyses between direct supplementation with free ncAAs and peptide conjugates illuminated the superior performance of the latter, particularly for low-permeability amino acids. For example, acetyl-lysine (AcK) presented enhanced incorporation efficiency when delivered as a Z-AisoK tripeptide compared to free AcK, highlighting the critical role of active transport in overcoming cellular membrane barriers. Remarkably, the delivery of lipoyl-lysine (LipK), a notably bulky ncAA with minimal cell permeability, was nearly undetectable via direct supplementation but became highly efficient in OppA-Z1 strains supplemented with the corresponding tripeptide. These results demonstrate that transporter-enabled import can surmount permeation bottlenecks, facilitating reliable and scalable ncAA incorporation.

Additionally, the study showcased the power of combining this uptake strategy with evolved aminoacyl-tRNA synthetase (aaRS)/tRNA pairs specific for respective ncAAs, achieving synthetase-promoted activation and incorporation inside the cell. Furthermore, the team demonstrated dual stop codon suppression utilizing a single isopeptide-linked tripeptide delivering two distinct ncAAs simultaneously, underscoring the method’s flexibility for multi-site protein engineering.

The implications of hijacking bacterial peptide transport for ncAA delivery extend far beyond laboratory protein synthesis. This technology paves the way for advanced synthetic biology applications, including the design of proteins with unnatural post-translational modifications, incorporation of chemical handles for bioorthogonal conjugation, and the production of novel therapeutics with enhanced stability, targeting, or novel mechanisms of action.

Future directions inspired by this research include further tailoring of peptide transporters to shuttle even more diverse chemical entities, exploring alternative bacterial hosts to extend the platform’s utility, and coupling this uptake mechanism with genome-integrated biosynthetic pathways for complete in vivo ncAA production and incorporation. The modularity of the Z-AisoK scaffold promises to be a versatile foundation for next-generation genetic code expansion efforts.

This study represents a compelling leap in our capacity to manipulate the proteome with precision and breadth, overcoming previous limitations imposed by cellular uptake and synthetic amino acid availability. By ingeniously co-opting natural bacterial transport mechanisms and enhancing them via protein engineering, the researchers have opened a new frontier in synthetic protein science, destined to reshape horizons across molecular biology, biotechnology, and medicine.

Subject of Research: Bacterial ABC transporters for genetic code expansion

Article Title: Hijacking a bacterial ABC transporter for genetic code expansion

Article References:
Iype, T., Fottner, M., Böhm, P. et al. Hijacking a bacterial ABC transporter for genetic code expansion. Nature (2025). https://doi.org/10.1038/s41586-025-09576-w

Traditional directed evolution techniques rely on iterative cycles of mutation and selection, typically requiring manual intervention and extended timeframes—often spanning weeks or months to achieve meaningful results. This laborious process involves repeated DNA manipulations, screening, and selection, limiting throughput and scalability. By contrast, T7-ORACLE integrates a remarkable genetic engineering feat: the establishment of a secondary, virus-derived DNA replication system within the well-studied bacterium Escherichia coli, which operates independently from the host’s genome replication. This orthogonal T7 replisome, derived from bacteriophage T7, introduces mutations at unprecedented rates—estimated to be 100,000 times higher than the natural background mutation frequency—exclusively targeting plasmid DNA while leaving the host genome untouched and thus preserving cellular viability.

The core innovation underpinning T7-ORACLE is the orthogonal replication system’s ability to achieve continuous, high-frequency mutagenesis focused on plasmids that harbor genes of interest. Through engineering the T7 DNA polymerase to be error-prone, researchers enable rapid and ongoing diversification of target proteins encoded on these plasmids without compromising host cell health. This decoupling of mutagenesis from the primary replication machinery circumvents common issues of genomic instability that plague other continuous evolution methods. As a result, the evolutionary process is synchronized with the bacterial division cycle, granting a new round of mutation and selection every approximately 20 minutes.

Current continuous evolution platforms have suffered from either technical complexity or insufficient mutation rates, limiting their practical utility in labs. T7-ORACLE addresses these challenges by combining the advantages of the T7 bacteriophage replication system with the genetically tractable, fast-growing E. coli model organism. This fusion not only drastically accelerates evolutionary timelines but also seamlessly integrates with standard molecular biology workflows. The system’s scalability and ease of use hold promise for widespread adoption in protein engineering efforts across academic and industrial settings.

To exemplify the capabilities of T7-ORACLE, the researchers implemented a proof-of-concept experiment using the TEM-1 β-lactamase gene—a prototypical enzyme conferring antibiotic resistance. By subjecting E. coli cells harboring the orthogonal replication system and TEM-1 variants to continuously escalating doses of diverse antibiotics, the team observed rapid emergence of evolved enzyme variants capable of tolerating antibiotic levels up to 5,000 times greater than the ancestral form. Remarkably, many of the mutations identified during this accelerated evolution closely mirrored those documented in clinical isolates, underscoring the system’s fidelity in recapitulating real-world evolutionary trajectories. Some evolved variants even exhibited novel mutational combinations that enhanced resistance beyond known clinical benchmarks.

Despite using antibiotic resistance as a demonstrative model, the implications of T7-ORACLE extend far beyond microbial resistance studies. The platform’s modularity enables it to evolve virtually any protein of interest—from human enzymes to viral antigens—simply by integrating the corresponding genes into plasmids compatible with E. coli. This opens expansive avenues for engineering next-generation biotherapeutics, including highly selective antibodies and proteases tailored to degrade disease-related proteins in cancer and neurodegenerative pathways. The rapid timeframe from gene insertion to evolved protein facilitates accelerated discovery and optimization cycles, dramatically reducing development pipelines.

The technical elegance of T7-ORACLE lies not only in its hypermutation rates but also in its preservation of host cell health. By confining mutagenic activity exclusively to the plasmid replicon, the system maintains genomic integrity and cellular viability—overcoming a crucial bottleneck that limits many mutagenesis-based approaches. This orthogonality is achieved through the design of a dedicated T7 replisome that operates independently of the host’s replication enzymes, a significant leap inspired by earlier orthogonal replication systems implemented in yeast (OrthoRep) and E. coli (EcORep). However, compared to these predecessors, T7-ORACLE offers a superior combination of rapid bacterial growth, high transformation efficiency, stringent mutagenesis, and compatibility with common laboratory techniques.

The broader vision for T7-ORACLE includes not only evolving proteins for improved or novel functions but also engineering entirely new biological polymers. Scientists involved envision extending the system to evolve specialized polymerases capable of replicating synthetic nucleic acids—chemical analogs of DNA and RNA with enhanced or altered properties. Such an advancement would usher in a new era of synthetic genomics, enabling the construction of organisms with fundamentally reprogrammed genetic architectures. This frontier remains largely unexplored but represents a tantalizing horizon for bioengineering and synthetic biology.

Importantly, the ease of implementing T7-ORACLE ensures accessibility for researchers already familiar with E. coli culture and standard molecular biology protocols. The platform does not require specialized equipment or complex workflows, lowering the barrier to entry for laboratories worldwide. This democratization of accelerated evolution technology could catalyze rapid advances across diverse areas of biomedical research, from drug development to environmental biocatalysis.

The development of T7-ORACLE reflects a paradigm shift in how scientists approach protein evolution. As co-senior author Pete Schultz articulates, the system acts as a “fast-forward button” on evolution, enabling the precise, continuous, and scalable generation of new protein variants with functional improvements. Co-senior author Christian Diercks reinforces that T7-ORACLE merges rational protein design principles with continuous evolution, creating a hybrid toolkit that will enhance efficiency in the discovery of therapeutic molecules.

Supported by funding from the National Institutes of Health, this study represents a milestone in synthetic biology and protein engineering. Its publication in Science signals broad recognition of the innovative methodology and its potential impact on medicine, research, and industrial biotechnology. As scientists continue to refine and expand T7-ORACLE, the system’s ability to rapidly produce specialized enzymes, antibodies, and other biologics could revolutionize approaches to treating cancer, neurodegeneration, and a myriad of human diseases.

Looking ahead, the research team at Scripps Research is focusing on applying T7-ORACLE to evolve human-derived enzymes for clinical use and to tailor proteases with enhanced specificity for cancer-associated proteins. These efforts aim to translate the platform’s accelerated evolutionary capability into tangible therapeutic applications, potentially speeding up drug development timelines and improving treatment efficacy. With T7-ORACLE, the promise of bringing evolution’s power directly into the laboratory has become a reality.

Subject of Research: Accelerated protein evolution using an orthogonal T7 plasmid replication system in Escherichia coli.

Article Title: An orthogonal T7 replisome for continuous hypermutation and accelerated evolution in E. coli.

News Publication Date: 7-Aug-2025.

Web References:
Science Article

Image Credits: Scripps Research.

Keywords: Proteins, Synthetic biology, Directed evolution, Hypermutation, E. coli, Orthogonal replication, Therapeutic enzymes, Antibiotic resistance, Protein engineering.